---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-063530"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-06-01T20:30:18+00:00"
generated_at: "2026-06-01T20:39:19.845460+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

## Summary
- 24% ORR (5 partial responses) among 21 efficacy-evaluable patients with recurrent/refractory gynecologic malignancies.
- 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors; one response >3 years.
- Median PFS of 20.5 months among 10 patients achieving clinical benefit (48% of evaluable patients).
- Safety manageable: only 1 reversible Grade 3 capillary leak syndrome at highest dose; no new safety signals.
- Phase 2 expansion study planned to further evaluate combination in gynecologic cancers including less heavily pre-treated patients.

## SEC filing metadata
- accession: 0001213900-26-063530
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-06-01T20:30:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/0001213900-26-063530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-063530
- JSON: https://secwatch.observer/filing/0001213900-26-063530.json
- Plain text: https://secwatch.observer/filing/0001213900-26-063530.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.